BioCryst: Jumps after submitting Japanese marketing application for swelling treatment

Torii Pharmaceutical Co

03/02/2020 16:31

** Shares of drug developer  BCRX.O  jump 9% to $3.1
    ** Company said it submitted Japanese marketing application
for its swelling disorder drug, berotralstat  urn:newsml:reuters.com:*:nGNX77KJgp
    ** Berotralstat has been developed for the prevention of
hereditary angioedema (HAE) attacks
    ** BCRX had submitted U.S. marketing application for
berotralstat in December, after trial data showed the drug
demonstrated statistical significance in reducing HAE attacks,
but missed market expectations  urn:newsml:reuters.com:*:nL4N28L2S9
    ** Company expects potential approval in H2 2020 
    ** Torii Pharmaceutical Co  4551.T  is BCRX's commercial
partner for the drug
    ** Company receives $22 mln upfront payment under the terms
of agreement; eligible to receive an additional milestone
payment of up to $20 mln based on approval 
    ** BCRX will also receive royalties of up to 40% of Japanese
net sales of berotralstat 
    ** Stock fell 57% in 2019

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))